BiotechTube
2A Pharma

2A Pharma

Stockholm, Sweden· Est.
2apharma.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $7.5M

Overview

2A Pharma is a private, clinical-stage biotech leveraging its patented AAVLP platform to develop next-generation vaccines. Its lead program is a prophylactic HPV vaccine in Phase 1, with a pipeline targeting infectious diseases, EpCAM+ cancers, and autoimmune conditions like vitiligo. The company's technology aims to offer broader coverage, improved safety, and lower production costs compared to existing vaccines, positioning it to address multi-billion-dollar unmet medical needs.

Infectious DiseasesOncologyAutoimmune Diseases

Technology Platform

Patented vaccine platform based on engineered adeno-associated virus-like particles (AAVLPs). These non-infectious protein scaffolds mimic viral structure to induce cellular and humoral immunity without viral DNA, enabling versatile antigen presentation with potential for broad coverage, improved safety, and lower production costs.

Pipeline

1
1 drug in pipeline
DrugIndicationStageWatch
AAVLP-HPV + PlaceboPapillomavirus InfectionsPhase 1

Funding History

2
Total raised:$7.5M
Seed$5M
Grant$2.5M

Opportunities

The AAVLP platform offers a potential first-in-class approach to therapeutic vaccines for autoimmune diseases and solid tumors, representing massive unmet needs.
Its lead prophylactic HPV vaccine, if successful, could capture market share by offering broader strain coverage than existing options.
The platform's design for low-cost production could enable competitive pricing and improved access in global health markets.

Risk Factors

High clinical development risk as all programs are in Phase 1 or earlier stages.
The company is pre-revenue and funding-dependent, with progress directly tied to capital availability.
It faces intense competition from large pharma and other biotechs in the vaccine and immunotherapy space.

Competitive Landscape

2A Pharma competes in the crowded vaccine and immuno-oncology space against giants like Merck, GSK, and Moderna, as well as numerous biotech platforms. Its differentiation hinges on the unique safety profile, cost structure, and broad-coverage claims of its AAVLP platform, which must be clinically validated to gain traction.

More companies in Immunotherapy / Immuno-Oncology →More companies in Sweden →